<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05080530</url>
  </required_header>
  <id_info>
    <org_study_id>BIDE-216D/2021</org_study_id>
    <nct_id>NCT05080530</nct_id>
  </id_info>
  <brief_title>Vitamin D and Painful Diabetic Neuropathy</brief_title>
  <official_title>Vitamin D (200 000 IU) for the Treatment of Painful Diabetic Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baqai Institute of Diabetology and Endocrinology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baqai Institute of Diabetology and Endocrinology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to evaluate the effect of vitamin D3 on diabetic&#xD;
      individual with painful neuropathy in a tertiary healthcare.&#xD;
&#xD;
      The people with diabetes (type 1 and type 2) who have a Douleur Neuropathique 4 (DN4) score&#xD;
      ≥4 will be considered eligible in this prospective study. Their serum samples will be&#xD;
      subjected to pre-and post-biochemical screening of serum 25 (OH) D and HbA1c. The individual&#xD;
      having Vitamin D insufficiency and deficiency will be administered a single dose of oral&#xD;
      Vitamin D3 (Soft Gel capsule 200,000 IU), and follow-up for post-biochemical screening after&#xD;
      3 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Painful diabetic neuropathy (PDN) is the most common diabetic complication in patients who&#xD;
      have had diabetes mellitus for a long time. Diabetic peripheral neuropathy is the common&#xD;
      cause of neuropathy globally. About 50-60% of individuals with long-term diabetes develop&#xD;
      diabetic neuropathy. Several recent observational studies in diabetic individuals have&#xD;
      provided a correlation between vitamin D insufficiency and diabetes. Despite the fact that&#xD;
      the pathogenesis of diabetic neuropathy is complex, recent investigations revealed that&#xD;
      deficiency of vitamin D is an important factor in the development of diabetic neuropathy.&#xD;
      Also, vitamin D supplementation was found to be effective in treating neuropathic pain and&#xD;
      preventing neuronal degeneration.&#xD;
&#xD;
      Aims and Objectives:&#xD;
&#xD;
      The assessment of the effect of single-dose, oral vitamin D in patients with painful diabetic&#xD;
      neuropathy.&#xD;
&#xD;
      Materials and Methods:&#xD;
&#xD;
      Study Drug: Oral cholecalciferol (Vitamin D3 capsule 200,000 IU).&#xD;
&#xD;
      A single oral dose of 200000 IU vitamin D will be administered in people with diabetic&#xD;
      neuropathy, and the effect will be observed after 3 months.&#xD;
&#xD;
        -  Sample size = 216 type 1 and 2 diabetic subjects&#xD;
&#xD;
        -  Recruitment time = 4 months&#xD;
&#xD;
        -  Treatment duration = 3 months&#xD;
&#xD;
      Ethical Approval:&#xD;
&#xD;
      The ethical approval for this study will be taken from the Institutional Review Board (IRB)&#xD;
      of Baqai Institute of Diabetology and Endocrinology (BIDE)&#xD;
&#xD;
      Study Area and Duration:&#xD;
&#xD;
      This study is going to be conducted from October 2021 to March 2022 in the outpatient&#xD;
      department (OPD) of BIDE.&#xD;
&#xD;
      Data Analysis and Statistics:&#xD;
&#xD;
      The primary analysis will compare the change from baseline. Comparisons within each treatment&#xD;
      group across time will also be considered. The analysis will be performed with the&#xD;
      Statistical Package for the Social Sciences (SPSS).&#xD;
&#xD;
      Assessment during the Treatment Period:&#xD;
&#xD;
        -  Change from baseline in DN4&#xD;
&#xD;
        -  Change from baseline in serum 25 (OH) D,&#xD;
&#xD;
        -  Change from baseline in HbA1c&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in DN4 score.</measure>
    <time_frame>3 months</time_frame>
    <description>The change will be observed with the help of neuropathic pain assessment questionnaire.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in serum HbA1c.</measure>
    <time_frame>3 months</time_frame>
    <description>The change will be observed in the serum values of glycated hemoglobin at the end point after the administration of vitamin D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in serum vitamin D.</measure>
    <time_frame>3 months</time_frame>
    <description>The cholecalciferol (Vitamin D) level in serum will be observed at the end point after the administration of vitamin D.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">216</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>1. Normal Vit D (&gt; 30ng/mL)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow-up after 3 months with standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2. Insufficient Vit D (20-30ng/mL)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose capsule 200,000 IU of Cholecalciferol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3. Insufficient Vit D (20-30ng/mL)</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Follow-up after 3 months with standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4. Deficient Vit D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single oral dose capsule 200,000 IU of Cholecalciferol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cholecalciferol</intervention_name>
    <description>Effect of Vitamin D on diabetic neuropathy symptoms</description>
    <arm_group_label>2. Insufficient Vit D (20-30ng/mL)</arm_group_label>
    <arm_group_label>4. Deficient Vit D</arm_group_label>
    <other_name>Sunny D™ (Vitamin D3) Softgel Capsule</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Insulin dependent diabetes&#xD;
&#xD;
          -  Insulin independent diabetes&#xD;
&#xD;
          -  Age range between 25 to 80 years&#xD;
&#xD;
          -  Glycated hemoglobin (HbA1c) level must be ≤11%&#xD;
&#xD;
          -  Apparently no symptoms of Vitamin D Deficiency&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hyperparathyroidism&#xD;
&#xD;
          -  Pregnant women&#xD;
&#xD;
          -  Lactating mothers&#xD;
&#xD;
          -  History for rickets and osteomalacia&#xD;
&#xD;
          -  On Vitamin D supplementation&#xD;
&#xD;
          -  On Multivitamin&#xD;
&#xD;
          -  On anti-epileptics&#xD;
&#xD;
          -  On steroids&#xD;
&#xD;
          -  On bisphosphonates&#xD;
&#xD;
          -  On oral contraceptives&#xD;
&#xD;
          -  Subjects who refuse to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdul Basit, Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baqai Institute of Diabetology and Endocrinology (BIDE)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abdul Basit, Professor</last_name>
    <phone>009221-36707179</phone>
    <email>research@bide.edu.pk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Asher Fawwad, Professor</last_name>
    <phone>009221-36707179</phone>
    <email>asherfawwad@bide.edu.pk</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2021</study_first_posted>
  <last_update_submitted>October 14, 2021</last_update_submitted>
  <last_update_submitted_qc>October 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baqai Institute of Diabetology and Endocrinology</investigator_affiliation>
    <investigator_full_name>Abdul Basit</investigator_full_name>
    <investigator_title>Professor of Medicine, and Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

